CLINICAL OUTCOMES AT STUDY-END ANALYSIS (N=31)1

PRIMARY ENDPOINT
OVERALL RESPONSE RATE (ORR)

39%

per independent review using
RECIST v1.1 (12/31 [efficacy
population]; 95% CI: 22%, 58%)1

Rapid Response

1.4months

median time to
response (95% CI: 1.3,
2.8 months)2

Durable Response

>3years

50% of patients had a DOR
of 39.7+ months (95% CI:
6.5 months to not reached)1

  • 7% complete response
  • 32% partial response
Responses that last

HALF OF RESPONDERS WERE STILL RESPONDING AFTER 3 YEARS1

HALF OF RESPONDERS WERE STILL RESPONDING AFTER 3 YEARS1

AMPECT=Advanced Malignant PEComa Trial; DOR=duration of response; PEComa=perivascular epithelioid cell tumor; RECIST=Response Evaluation Criteria in Solid Tumors.

References: 1. Wagner AJ, Ravi V, Riedel RF, et al. Phase II trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): long-term efficacy and safety update. J Clin Oncol. Published online March 1, 2024. doi.org/10.1200/JCO.23.02266 2. Wagner AJ, Ravi V, Riedel RF, et al. nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors. J Clin Oncol. 2021;39(33):3660-3670. doi:10.1200/JCO.21.01728